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Abstract:  
 
Background: Human respiratory syncytial virus (hRSV) is the leading cause of upper and lower 
respiratory infection in infants, adults and immunocompromised persons. The matrix protein, M2-1 of 
hRSV is a cofactor of viral RNA polymerase that plays a crucial role during replication. This 
programmed study was designed to scrutinize potential immunogens from the M2-1 protein 
characterized from four different continents.  
Methods: Sequence data obtained from NCBI databases were analysed by using a series of web and 
software based bioinformatics tools to find out the best epitope against hRSV.                                 
Results: The phylogenetic data revealed a homogenized clustering of M2-1 protein for the African, 
European, and Asian clades while proteins from North American collections found to have a significant 
evolutionary detachment compared to three other clusters. Using various web-based bioinformatics 
tools, the study identified four common B-cell epitopes present in all the M2-1 proteins from four 
different clusters with higher antigenicity and conservancy. Among the 17 M2-1 protein investigated 
for T-cell epitopes, “VLQNLDVGL” peptide from A2 super-type, and “QSACVAMSK” and “CLNGRRCHY” 
from A3 super-type showed the highest antigenicity at >0.80 conservancy cut-off value. After 
evaluation of all antigenic properties, only “CLNGRRCHY” peptide qualified as a potential vaccine 
candidate against hRSV. Molecular docking revealed strong and stable binding of the epitope to major 
histocompatibility complexes (MHC) molecules in terms of hydrogen bonding.                  
Conclusion: The designed epitope could be used as a possible vaccine candidate against hRSV. 
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Abstrait 
Contexte: Le virus respiratoire syncytial (VRSH) humain est la principale cause d'infection des voies 
respiratoires supérieures et inférieures chez les nourrissons, les adultes et les personnes 
immunodéprimées. La protéine matricielle M2-1 du hRSV est un cofacteur de l'ARN polymérase virale 
qui joue un rôle crucial lors de la réplication. Cette étude programmée a été conçue pour examiner les 
immunogènes potentiels de la                        
Méthodes: Les données de séquence obtenues des bases de données NCBI ont été analysées à l'aide 
d'une série d'outils bioinformatiques basés sur le Web et sur les logiciels, afin de déterminer le 
meilleur épitope contre le hRSV.                       
Résultats: Les données phylogénétiques ont révélé un regroupement homogénéisé de la protéine M2-
1 pour les clades africain, européen et asiatique, tandis que les protéines des collections nord-
américaines se sont révélées avoir un important détachement évolutif par rapport à trois autres 
groupes. À l'aide de divers outils bioinformatiques basés sur le Web, l'étude a identifié quatre épitopes 
de cellules B communs présents dans toutes les protéines M2-1 de quatre groupes différents 
présentant une antigénicité et une conservation plus élevées. Parmi les 17 protéines M2-1 étudiées 
pour les épitopes de lymphocytes T, le peptide «VLQNLDVGL» de super type A2, et «QSACVAMSK» et 
«CLNGRRCHY» de super type A3 ont montré la plus grande antigénicité à une valeur de coupure> 
0,80. Après évaluation de toutes les propriétés antigéniques, seul le peptide «CLNGRRCHY» a été 
qualifié de candidat vaccin potentiel contre le hRSV. L'amarrage moléculaire a révélé une liaison forte 
et stable de l'épitope aux molécules du complexe majeur d'histocompatibilité (MHC) en termes de 
liaison hydrogène.                         
Conclusion: l'épitope conçu pourrait être utilisé comme vaccin potentiel contre le hRSV. 
Mots-clés: hRSV; Protéine M2-1; groupe phylogénétique; Épitopes BCL et CTL; amarrage molèculaire 
Introduction 
 Bronchiolitis is a severe respiratory 
tract infection caused by Paramyxoviridae 
family virus, human respiratory syncytial 
virus (hRSV). It is the leading cause of 
mortality in children under two years of 
age (1). It has also been reported to infect 
elderly and immunocompromised people, 
especially pregnant women and transplant 
patients (2, 3). Currently, there is no 
candidate vaccine or drug available to 
prevent hRSV infection in the young and 
adults. Although, some of the drugs 
showed promising preclinical trial results, 
their long-term application remained 
challenging due to problem of post-clinical 
trial development, adverse effects 
including allergenicity, and short-term 
efficacy in humans (4, 5). For instance, 
treatment with ribavirin is not only 
expensive but the drug also cause aerosol 
related side-effects (6).   
 M2-1 protein is an essential co-
factor of hRSV viral RNA polymerase 
complex that plays a crucial function in 
transcription processivity, acting as an 
anti-termination factor. The M2-1 protein 
binds to RNA dependent RNA polymerase 
(RdRp) and also interacts with other 
components of viral RNA polymerase by 
its core domain at the N-terminus (7, 8). 
Inhibition of M2-1 protein activity caused 
a significant reduction of viral RNA 
transcription and viral assembly (7).  
 In-silico epitope-based drug design 
can provide rapid, reliable, inexpensive, 
and safe vaccine against targeted antigen 
using immunoinformatics platforms. 
Epitopes are usually 9–mer peptides from 
viral proteins that can generate potent 
antigenicity when directed against specific 
antigen(s) (9). In the post-genomic era, 
epitope-based computer-aided vaccine has 
proven to be successful against most of 
the pathogenic viruses including human 
viral pathogens such as Influenza, 
Chikungunya, Rota, Zika, Ebola, MARS-
CoV, etc., and fish pathogens such as 
Edwardsiella, Flavobacterium, and shrimp 




white spot virus (WSSV) (9–17). In 
humans particularly, proper definition and 
differentiation of major histocompatibility 
complex molecules (MHC class I and II), 
human leucocyte antigen (HLA), and 
readily available enhanced databases, 
make in-silico approach widely acceptable 
for vaccine design against viral and 
bacterial pathogens (17). The aim of the 
present study therefore was to discover 
potent B-cell and T-cell epitope(s) from 
the M2-1 matrix protein that can bind 
strongly to human MHC molecules and 
subsequently inhibit RSV replication in the 
host cell.   
Materials and methods:  
Retrieval of M2-1 protein sequences 
from the database                 
 M2-1 protein sequences were 
downloaded in FASTA format from the 
National Center for Biotechnology 
Information (NCBI) protein data bases 
(https://www.ncbi.nlm.nih.gov/protein). M2-1 
protein was selected for antigenicity 
screening and downstream bioinformatics 
analysis because of its role and 
association during respiratory infection 
(5,18,19). In the present study, we 
collected information on 17 M2-1 protein 
sequences from four different continents 
namely Asia, Africa, Europe, and North 
America for further immunoinformatics. 
 Although information about the 
epidemiology of hRSV infections is sparse 
in the literature, several outbreaks have 
been reported from these four continents 
(20, 21). Sequences having same isolation 
history and date were excluded in the 
present study.  
Phylogenetic clustering   
 Extracted protein sequences were 
aligned using muscle alignment program 
in MEGA 7.0. Muscle alignment has been 
reported to be a highly efficient tool for 
protein sequence alignment and 
phylogenetic analysis (22). The 
phylogenetic tree was constructed by the 
neighbour-joining method in MEGA 7.0 
using Kimura-J model where branches in 
the tree separated by 1000 bootstrap 
replicate (22). The evolutionary 
divergence in tree was calculated as p-
distance for both transition and trans-
version in default parameters.                     
Sorting antigenic protein  
 To determine the antigenic protein 
of M2-1 that can elicit necessary immune 
response, we used VaxiJen (v2.0) online 
based server (http://ddg-
pharmfac.net/vaxijen/VaxiJen/VaxiJen.ht
ml) for the classification of 17 sequences 
based on immunity score. This server can 
predict antigenicity of any protein 
sequence with 90% accuracy, and 
therefore, widely used for in-silico based 
drug design (23). The highest antigenic 
M2-1 sequences were selected for further 
studies. 
Prediction of B-cell linear (BCL) 
epitopes                         
 Immune Epitope Database (IDEB) 
(http://tools.iedb.org/main/) has different 
antigenicity analysis tools based on the 
protein sequences. Among the 
approaches, Kolaskar and Tongaonkar 
1990 method has been widely used for B-
cell linear epitope prediction due to its 
accuracy (>75%) (9). The tool can also 
efficiently stratify epitopes from the large 
group of protein sequences based on 
antigenic scores (17).  
Helper T-lymphocytes (HTL) epitopes 
prediction                  
 HTLs epitopes from the M2-1 
protein sequences from four different 
clusters were screened by utilizing IEDB 
database for class II epitope prediction 
tool (http://tools.iedb.org/mhcii/) (24). In 
the webpage of IEDB, various prediction 
methods are available, but we chose the 
recommended option for the finding of 
best epitopes, and followed the process 
described earlier (25). The human was 
selected as the targeted species and 
recommended 27 MHC alleles were 
screened with >99% population coverage 
(26).      
 The selected MHC II alleles were; 
(i) HLA DRB1⁄01:01; (ii) HLA DRB1⁄03:01; 
(iii) HLA DRB1⁄04:01; (iv) HLA 
DRB1⁄04:05; (v) HLA DRB1/07:01; (vi) 
HLA DRB1⁄08:02; (vii) HLA DRB1⁄09:01; 




(viii) HLA DRB1⁄11:01; (ix) HLA 
DRB1⁄12:01; (x) HLA DRB1⁄13:02;              
(xi) HLA DRB1⁄15:01; (xii) HLA 
DRB3⁄01:01; (xiii) HLA DRB3⁄02:02; (xiv) 
HLA DRB4⁄01:01; (xv) HLA DRB5⁄01:01; 
(xvi) HLA DQA1⁄05:01/DQB1⁄02:01;  
(xvii) HLA DQA1⁄05:01/DQB1⁄03:01; 
(xviii) HLA DQA1⁄03:01/DQB1⁄03:02; 
(xix) HLA DQA1⁄04:01/DQB1⁄04:02; (xx) 
HLA DQA1⁄01:01/DQB1⁄05:01; (xxi) HLA 
DQA1⁄01:02/DQB1⁄06:02; (xxii) HLA 
DPA1⁄02:01/DPB1⁄01:01; (xxiii) HLA 
DPA1⁄01:03/DPB1⁄02:01; (xxiv) HLA 
DPA1⁄01/DPB1⁄04:01; (xxv) HLA 
DPA1⁄03:01/DPB1⁄04:02; (xxvi) HLA 
DPA1⁄02:01/DPB1⁄05:01 and (xxvii) HLA 
DPA1⁄02:01/DPB1⁄14:01. During HTL 
epitope screening, allelic population 
coverage for four different clusters were 
taken into consideration so as to find more 
epitopes for wider coverage (>1 clusters). 
Cytotoxic T lymphocyte epitopes 
prediction and conservancy analysis  
 Cytotoxic T-cells play a crucial role 
in generating MHC class I cellular 
response. They usually performed various 
functions including destruction of 
damaged, unresponsive, infected and 
cancerous cells by recognizing presented 
epitopes by MHC molecules on the cell 
surface. The CTL epitopes that can bind 
MHC class I molecule were predicted from 
CTLPred (http://crdd.osdd.net/raghava/ctlpred/) 
(27). The MHC binding ability of the 
predicted epitopes was measured by 
implementation of the artificial neural 
network (ANN) and stabilized matrix 
method implementation (SMM) at 
sensitivity cut-off value of 0.80. The 9-
mer peptide (length) was selected 
because of its high binding ability (>75%) 
to MHC class I and class II molecules 
(28). The super-type A2, A3, and A7 were 
selected as a subtype to cover 
approximately 90% of the population 
around the globe (29).  The C-terminal 
cleavage weight and tap transport 
efficiency cut-off value were set at 0.15 
and 0.05, respectively.   
 The prediction threshold score was 
set at 0.80. The predicted binding scores 
of the CTL peptides against major human 
MHC molecules were calculated from the 
T-epitope designer portal 
http://www.bioinformation.net/script/hla_search.cgi.
As conserved epitopes can provide border 
protection, therefore, we aimed to identify 
peptides with the higher conservancy. The 
conservancy values of the CTL epitopes 
were calculated from the IEDB 
conservancy analysis tool using NCBI 
protein reference data set NCBI 
(http://tools.iedb.org/ncbi_seq_browser/) 
(26). 
Allergenicity of the predicted epitopes
 The selection of non-allergen 
epitopes was one of the prime aims of this 
study. The allergenicity of the final 
epitopes those from four different clusters, 
having higher antigenicity scores and MHC 
binding affinity were evaluated using 
AllerTOP (v2.0) server at 
http://www.pharmfac.net/allertop/. This 
server transforms auto-cross covariance 
(ACC) into equal length vectors. Then the 
server classifies the protein to either 
known allergen or non-allergen based on 
the k-nearest neighbouring score after 
comparing 4420 allergenic and non-
allergenic proteins from the same and 
different species (25). 
Structure prediction and molecular 
docking of the peptide to MHC 
molecules                      
 PEP-FOLD3 is a denovo peptide 
prediction server (http://bioserv.rpbs.univ-
paris-diderot.fr/services/PEP-FOLD3/) from 
corresponding amino acid sequences. PEP-
FOLD3 can generate 3D models of 
peptide-based on greedy strategy by 
using information from the input epitope 
sequences (30). Molecular docking is the 
widely used tool to measure the binding 
affinity of any ligand to receptor molecules 
(31). Molecular docking of predicted of the 
predicted peptide to human leucocyte 
antigens, HLA-A0201 (PDB code 1HLA) 
and HLA-B*3508 (PDB code 1ZHL) were 
performed in CABS-DOCK server 
(http://biocomp.chem.uw.edu.pl/CABSdock) 
with default parameters. CABS-dock 
provides efficient and flexible docking with 
high accuracies (>80%) without 
predefined localization of the binding sites 




(32, 33). Visualization tool PyMol (v2.0.5) 
was used to extract the 3D structure of 
docked protein-peptide complexes. The 
PyMol graphics system is capable of 
providing excellent visualization platform 
for analysing the efficacy of computer-
aided drugs (34). 
Population coverage                
 Population coverage is usually used 
to check whether the predicted final 
epitope and its HLA alleles can cover a 
significant percent of the world population 
or not. The IEDB population coverage tool 
(http://tools.immuneepitope.org/tools/pop
ulation/iedb) was used to calculate the 
cumulative percent of world wide 
population coverage for the final predicted 
epitope for both MHC classes, as described 
previously (35). 
Results:  
Phylogeny and antigenicity of M2-1 
protein sequences from four different 
clusters     
 Analysis of 17 M2-1 hRSV proteins 
from four different geographic locations 
revealed uniform clustering of sequences 
from Asian, African, and European 
continents. However, North American 
(USA) cluster had significant evolutionary 
divergence and distributed erratically in 
the phylogenetic tree (Figure 1).
 Multiple alignments using muscle 
found a highly conserved region in M2-1 
protein for all four clusters in position 7-
26 and 82-101. The protein sequence 
Q5MKM1.1 from North American (USA) 
cluster had the highest evolutionary 
detachment value of 0.579 with other M2-
1 sequences, followed by Q84132.1 
(detachment value 0.164). African M2-1 
protein cluster was found to be 
phylogenetically more detached from the 
other three groups. Preliminary screening 
of antigenicity for 17 M2-1 protein 
revealed Q84132.1 as the highest 
antigenic protein with the value of 0.5063, 
followed by Q5MKM1.1 (0.4787), 
APW78912.1 (0.4647, European cluster), 
APW78659.1 (0.4647, European cluster) 
respectively (Table 1). 
Table 1: VaxiJen score of RSV M2-1 protein from four different clusters 
Accession number VaxiJen Score Cluster 
NP_056864.1 0.4 North American Cluster (NAC) 
Q84132.1 0.5063 NAC 
Q5MKM1.1 0.4787 NAC 
AIY60641.1 0.4134 NAC 
ASV49500.1 0.4087 NAC 
APW78912.1 0.4647 European Cluster (EC) 
APW78692.1 0.4615 EC 
APW78681.1 0.4627 EC 
APW78659.1 0.4647 EC 
APW78868.1 0.4615 EC 
AGN92849.1 0.4189 Asian Cluster (AC) 
AGN92838.1 0.4189 AC 
AOD40569.1 0.4164 African Cluster (AFC) 
AOD41194.1 0.4172 AFC 
AOD41183.1 0.4172 AFC 
AOD41018.1 0.4172 AFC 
AOD40803.1 0.4172 AFC 
 
BCL, HTL, and CTL epitopes prediction
 The present study found 23 B-cell 
linear epitopes from various sequence 
positions of 17 M2-1 proteins from four 
different clusters (Table 2). Among  them, 
 
Table 2: Antigenic properties of 23 linear B-cell epitopes of RSV M2-1 protein from four 
different clusters 
Rank Sequence Start 
position 
Score Cluster 
1 YFEWPPHALLVRQNFMLNKI 27 0.88 NAC, EC 
2 VYNTVISYIESNRKNNKQTI 127 0.86 NAC, EC, AC 
3 KNNKQTIHLLKRLPADVLKK 140 0.85 NAC, EC 
4 SYIGSINNITKQSACVAMSK 82 0.84 NAC, EC, AC, AFC 
5 CKFEIRGHCLNGRRCHYSHN 7 0.84 NAC, EC, AC, AFC 
6 SACVAMSKLLIEINSDDIKK 94 0.83 NAC, AC 
7 LIEINSDDIKKLRDNEEPNS 103 0.83 NAC, EC, AC, AFC 
8 KTIKNTLDIHKSIIISNPKE 159 0.82 NAC, EC, AC, AFC 
9 NGRRCHYSHNYFEWPPHALL 17 0.81 NAC, EC 
10 PHALLVRQNFMLNKILKSMD 32 0.88 NAC, AC, AFC 
11 RNPCKYEIRGHCLNGKKCHF 4 0.84 NAC 
12 VISYIDSNKRNPKQTIHLLK 131 0.82 NAC 
13 LGSVNNITKQSACVAMSKLL 84 0.8 NAC 
14 KYSHKYWEWPLKTLMLRQNY 21 0.86 NAC 
15 IACGSLITVLQNLDVGLVIQ 93 0.82 NAC 
16 FDAPQRTAEYALGTIGVLKS 62 0.82 NAC 
17 NTDAMSDVSGFDAPQRTAEY 52 0.82 NAC 
18 GVLCNLIQSVISIEEKINSS 153 0.82 NAC 
19 ESNRKNNKQTIHLLKRLPAD 130 0.84 AFC 
20 PNSPKVRVYNTVISYIESNR 114 0.84 AFC 
21 LLKRLPADVLKKTIKNTLDI 142 0.81 AFC 
22 VRVYNTVISYIESNRKNNKQ 125 0.84 AFC 
23 NRKNNKQTIHLLKRLPADVL 138 0.83 AC 
 
 






Figure 1: Phylogenetic clustering of 17 HRSV M2-1 Proteins from four different continents. 
African, Asian, North America, and European clusters are symbolized in black, green, red, 
and blue colours. The percentages of the replicate in trees in which the associated taxa 
clustered together by the bootstrap test (1000 replicates) are shown next to the branches. 
The tree was constructed using neighbour-joining method in mega7. 
 
four were common in all four clusters (AC, 
AFC, EC, and NAC). Out of the four, 
epitope “SYIGSINNITKQSACVAMSK” and 
“CKFEIRGHCLNGRRCHYSHN” had higher 
antigenicity value of 0.84 compared to 
other two in the clusters. Among these 
two, the threshold of antigenicity for 
“CKFEIRGHCLNGRRCHYSHN” (1.039, only 
one residue had a score of below 1) was 
noticeably higher compared to 
“SYIGSINNITKQSACVAMSK” (1.028, seven 
residues had a score of below 1). 
 We found ten potential HTL 
epitopes candidate after the screening of a 
diverse set of alleles (Table 3). However, 
the majority of the epitopes were from 
HLA-DRB1*01:01 allele and some them 
had sequence similarity with BCL linear 
epitopes. CTL peptides are the potential 
vaccine candidates for the control of 
diseases. After screening of three main 
super type class, we found one common 
epitope “LLVRQNFML” in A2 with higher 
antigenicity (0.7122) and conservancy 
(1.03).      
Table 3: HTL epitopes among matrix protein of hRSV 
ID Epitope Allele Method 
74635 YLEKESIYY HLA-DRB1*01:01 Consensus 
28122 IPYSGLLLV HLA-DRB3*01:01 Consensus 
95757 RFAIKPME HLA-DRB1*11:01 Consensus 
121876 SRSALLAQM HLA-DRB4*01:01 Consensus 
122004 VRNKCLNGRR HLA-DRB1*01:01 Consensus 
144866 AITNAKII HLA-DPA1*02:01/ 
DPB1*01:01 
Consensus 
542935 ILVKQISTPKGPS HLA-DPA1*02:01 Consensus 
546171 VNILVKQISTPKGPS HLA-DRB4*01:01 Consensus 
546172 VNILVKQISTPKGPSL HLA-DRB5*01:01 Consensus 
546173 VNILVKQISTPKGPSLR HLA-DRB1*01:01 Consensus 
 
 




 Two epitopes “CLNGRRCHY” and 
“QSACVAMSK” from A3 super type were 
common in 15 out of 17 M2-1 proteins 
from four different clusters with 
antigenicity and conservancy score of 
1.2599, 1.4418 and 0.8527, 1.3972, 
respectively (Table 4)  
 
 
Table 4: Antigenic properties of major T-cell epitopes of RSV M2-1 protein from four different clusters at 0.80 conservancy 
Accession 
number 
T-cell antigen Super type VaxiJen Score Conservancy (<-E) 
NP056864.1 LLVRQNFML A2 super type 0.7122 1.0329 






QSACVAMSK 1.4418 1.3972 
ISYIESNRK 0.6024 1.278 
KQTIHLLKR 0.4361 0.8701 
KSIIISNPK 0.5318 1.1139 
Q84132.1 LLVRQNFML A2 super type 
 
0.7122 1.0329 
SMDRSNDTL 0.428 0.8539 
QSACVAMSK A3 super type 
 
1.4418 1.4542 
KQTIHLLKR 0.4361 0.8558 
Q5MKM1.1 LMLRQNYML A2 super type 
 
0.6751 1.1108 
VLQNLDVGL 2.1681 0.9847 




ALGTIGVLK 0.8243 1.3255 
RQIIHILKR 0.5421 0.8231 
LPVGVLCNL B7 super type 0.4009 0.8792 
AIY60641.1 LLVRQNFML A2 super type 0.7122 1.03366 




ISYIESNRK 0.6024 1.278 
KQTIHLLKR 0.4361 0.8701 
ASV49500.1 LLVRQNFML A2 super type 0.7122 1.0366 




ISYIESNRK 0.6024 1.278 
KQTIHLLKR 0.4361 0.8701 
APW78912.1 LLVRQNFML A2 super type 0.7122 1.0329 






QSACVAMSK 1.4418 1.3972 
ISYIESNRK 0.6024 1.282 
KQTIHLLKR 0.4361 0.8657 
KSITISNPK 0.8562 1.2084 
APW78692.1 LLVRQNFML A2 super type 0.7122 1.0329 






QSACVAMSK 1.4418 1.3972 
ISYIESNRK 0.6024 1.282 
KQTIHLLKR 0.4361 0.8657 
KSITISNPK 0.8562 1.2091 
APW78681.1 LLVRQNFML A2 super type 0.7122 1.0329 









ISYIESNRK 0.6024 1.282 
KQTIHLLKR 0.4361 0.8652 
KSITISNPK 0.8562 1.2091 
APW78659.1 LLVRQNFML A2 super type 0.7122 1.0329 






QSACVAMSK 1.4418 1.3972 
ISYIESNRK 0.6024 1.282 
KQTIHLLKR 0.4361 0.8652 
KSITISNPK 0.8562 1.2084 
APW78868.1 LLVRQNFML A2 super type 0.7122 1.0329 






QSACVAMSK 1.4418 1.3972 
ISYIESNRK 0.6024 1.282 
KQTIHLLKR 0.4361 0.8657 
KSITISNPK 0.8562 1.2091 
AGN92849.1 LLVRQNFML A2 super type 0.7122 1.0366 




ISYIESNRK 0.6024 1.278 
KQTIHLLKR 0.4361 0.8701 
AGN92838.1 LLVRQNFML A2 super type 0.7122 1.0366 




ISYIESNRK 0.6024 1.278 
KQTIHLLKR 0.4361 0.8701 
AOD40569.1 LLVRQNFML A2 super type 0.7122 1.0366 




ISYIESNRK 0.6024 1.278 
KQTIHLLKR 0.4361 0.8701 
AOD41194.1 LLVRQNFML A2 super type 0.7122 1.0366 




ISYIESNRK 0.6024 1.278 
KQTIHLLKR 0.4361 0.8701 
AOD41183.1 LLVRQNFML A2 super type 0.7122 1.0366 




ISYIESNRK 0.6024 1.278 
KQTIHLLKR 0.4361 0.8701 
AOD41018.1 LLVRQNFML A2 super type 0.7122 1.0366 




ISYIESNRK 0.6024 1.278 
KQTIHLLKR 0.4361 0.8701 
AOD40803.1 LLVRQNFML A2 super type 0.7122 1.0366 




ISYIESNRK 0.6024 1.278 
KQTIHLLKR 0.4361 0.8701 




 Epitope “LLVRQNFML” failed to 
produce a satisfactory binding score with 
MHC molecule during scoring from the T-
epitope designer website while positive 
scores recorded for “CLNGRRCHY” and 
“QSACVAMSK” epitopes against major HLA 
types.    
Allergenicity of the predicted epitopes 
 The predicted peptide should be 
non-allergen in order to be considered as 
the safe vaccine. Among the final two 
selected epitopes, “QSACVAMSK” 
classified as “probable allergen” by the 
AllerTop database while “CLNGRRCHY” 
categorized as “probable non-allergen”. 
Therefore, epitope “QSACVAMSK” was 
excluded for further studies. 
Molecular docking of the peptide to 
MHC molecules    
 The structure of the predicted CTL 
epitope, “CLNGRRCHY” in PEP-FOLD3 with 
residues is shown in Figure 2. Molecular 
docking image of “CLNGRRCHY” to human 
MHC class I antigen, HLA-A2 (PDB code 
1HLA) and MHC class II antigen, HLA-
DRB1*04:01 (PDB code 5NIG) are 
presented in Figure 3. The designed 
peptide produced strong and stable 
binding with both MHC class I and II 
regarding hydrogen bonds. In the first 
case (peptide to 1HLA), the designed 
epitope formed seven hydrogen bonds, six 
(CYS, ARG, TYR, HIS) of which had a bond 
resolution of more than 3 °A. While in 
second interaction (peptide to 1ZHL), 
peptide-protein interaction aided by six 
hydrogen bonds, four (CYS, GLY, ARG) of 






Figure 2: Modelled 3D structure of predicted “CLNGRRCHY” epitope using pep-fold3 
 
 





Figure 3: Molecular docking of the predicted epitope to HLA-A*0201, PDB-1HLA (left) and 
HLA-B*3508, PDB-1ZHL (right). The epitope “CLNGRRCHY” bound perfectly to the binding 
groove of MHC molecules in terms of strong hydrogen bonds (>3 °A). 
 
Binding properties and population 
coverage of the predicted epitope 
 The binding properties of 
“CLNGRRCHY” revealed the percentile 
rank of epitope ranged from 0.4-0.75 in 
consensus method (ANN and SMM) and 
IC50 ranged from 135.87-553.88 for both 
ANN and SMM (Table 5).  The deigned 
epitope covered 98.84% of world 
population with average hit of 2.57 and 
PC90 value of 1.04 by taking both class I 
and class II in counts where all major 
alleles (HLA-A*02:01, HLA-A*02:02, HLA-
A*02:03, HLA-A*02:06, HLA-A*68:02, 
HLA-B*07:02, HLA-B*08:01, HLA-
C*01:02, HLA-C*02:02, HLA-C*05:01) 
were taken into consideration (Figure 4). 
 
 
Figure 4: The world population coverage of predicted epitope based on MHC Restriction 
data. The cumulative coverage was 98.84% based on recommended ten HLA class. 









 In the present study, we aimed to 
identify the key antigenic epitope(s) with 
all necessary properties that can 
eventually bind strongly to MHC molecules 
to generate immunogenicity against hRSV. 
Several studies have been conducted to 
proffer solution to this, however no 
vaccine is yet to be licensed for hRSV 
(36). Transcription anti-termination factor 
M2-1 has been reported to be involved in 
viral replication and inactivation of M2-1 
protein triggered inhibition of hRSV in-vivo 
(5). Hence, we selected this protein for in-
silico drug design study.   
 The phylogenetic and evolutionary 
data suggested that the M2-1 protein from 
North America had more detachment and 
clustered everywhere. Therefore, we 
assumed that North America (NA) could 
be a potential source of hRSV 
transmission around the globe. However, 
these clusters had significantly higher 
bootstrap value (99%) and that means 
taxa’s are well-supported by the reported 
data. We found more antigenicity in the 
M2-1 protein from the NA cluster, a well-
studied sequence that can be a candidate 
vaccine. The four common BCL epitopes in 
17 M2-1 protein sequences was one of the 
major findings in this study. A vaccine 
from one of these epitopes hereafter can 
inhibit hRSV from anywhere in the world. 
The sequence similarity of HTL and CTL 
epitopes with the BCL epitopes revealed 
more accuracies and wider coverage of 
the predicted peptides.    
 B-lymphocytes and hyper T-
lymphocytes (HTLs) are the key players of 
adaptive immune response. They are the 
primary factors of the immune response 
mediated by activation of B-cells, 
cytotoxic T-cells and macrophages (9, 
25). CTL peptides play a central role in 
governing adaptive immune response 
against broad range of infections (17). We 
comprehensively screened BCL, HTL, and 
CTL epitopes from M2-1 protein with 
consistency and flow strictly maintained. 
The two selected BCL epitopes were 
separately evaluated by a wide range of 
antigenic properties where 
“CKFEIRGHCLNGRRCHYSHN” showed its 
superiority over other.   
 Finally, among four CTL epitopes, 
only “CLNGRRCHY” qualified for all the 
necessary properties to be used as a 
candidate vaccine. Other three were 
excluded due to allergenicity, low affinity, 
and coverage. The conservancy values of 
selected BCL and CTL epitopes were more 
than 80%, a standard value to generate 
broad-spectrum antigenicity, and well-
desired criteria for any predicted epitopes 
(17,37). A potential binder (epitope) 
should have three characteristics in order 
to generate strong immunogenicity, (i) an 
IC50 value of less than 500nM, (ii) 
percentile rank of below 1.5%, and (iii) 
population coverage of more than 80% 
(35,38). We found satisfactory IC50 value 
and percentile rank in our predicted 
epitope and population coverage of more 
than 98%, therefore, could be a potential 
immunogen against hRSV.   
 In molecular docking, epitope 
“CLNGRRCHY” formed strong and stable 
binding with MHC molecules. Usually, four 
hydrogen bonds are required to consider 
peptide as a strong binder of MHC 
molecules (16). Here we found seven 
(HLA-A2) and six hydrogen bonds (HLA-
B*3508) in our protein-peptide dock for 
where nine formed a very strong and 
steady bond (> 3 °A) with both classes of 
HLA molecules. In both cases, arginine 
(R), cysteine (C), histidine (H), and 
tyrosine (Y) play a key role in protein 
binding. Arginine is strong protein binders 
which stabilize protein-protein interaction 
from aggregation, especially during the 
process of folding (39). These four amino 
acids have been used for the induction of 
protein binding ability of peptides in many 
vaccine preparation against broad range 
of diseases including cancer, pneumonia, 
and malaria (40–43). The introduction of 
cysteine zipper in the candidate vaccine 
leads to formation of inter-promoter 
disulfide rings that enabled stable coiled-
coil trimers, generating satisfactory 
immunogenicity against hRSV (44). 
 Recent advances in bioinformatics 
have led to the rapid design of epitope-
based vaccine against many human 




pathogens. This method saves significant 
amount of time compared to previous 
lengthier vaccine design and long-lasting 
clinical trials. After analysing all the 
parameters, we hope that our designed 
epitope has all the necessary criteria as a 
future candidate vaccine that could 
produce protective neutralizing antibodies 
and cell-mediated immune responses to 
hRSV. Further synthesis and in-vivo 
laboratory trials are required to determine 
the exact potency of the designed epitope 
before commercial release.  
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